Human Complement fragment 3b rccptor ELISA kit

Structural and magnetic properties of the spinel compound, Li0.5FeCr1.5O4, have been investigated using dc magnetization, neutron depolarization, and neutron diffraction techniques. DC magnetization measurement at 200 Oe has revealed a ferrimagnetic ordering at 417 K and a negative magnetization state between the two compensation temperatures (T-Comp) of 244 and 256 K. T-Comp varies with an applied magnetic field and two T-Comp merge at 256 K for magnetic fields >= 500 Oe. The existence of zero domain magnetization around T-Comp is evident from full recovery of the transmitted neutron beam polarization in a neutron depolarization study. The Rietveld refinement of the neutron diffraction pattern at 430 K reveals that the compound possesses a face centred cubic structure with Fe0.81Li0.19 and Cr1.5Li0.31Fe0.19 as cation distributions at the tetrahedral and octahedral sites, respectively. A temperature dependent neutron diffraction study reveals that the net magnetic moment changes sign near 265 K, across the spin compensation temperature. Both neutron diffraction and mean field calculation show that an asymmetric variation of the sublattice moments as a function of temperature yields a dominance of the ordered tetrahedral site moment over the octahedral site moment below T-Comp, and vice versa above T-Comp, and gives a microscopic understanding of the observed magnetization reversal phenomenon. The achieved understanding of magnetization compensation and the high coercivity near T-Comp have implications for possible use of such ferrimagnetic materials with finite spin polarization as effective spin polarizers/analyzers in spintronic devices.

Natural killer (NK) cells are an emerging immunotherapy approach to acute myeloid leukemia (AML); however, the optimal approach to activate NK cells before adoptive transfer remains unclear. Human NK cells that are primed with the CTV-1 leukemia cell line lysate CNDO-109 exhibit enhanced cytotoxicity against NK cell-resistant cell lines. To translate this finding to the clinic, CNDO-109-activated NK cells (CNDO-109-NK cells) isolated from related HLA-haploidentical donors were evaluated in a phase 1 dose-escalation trial at doses of 3 x 10(5) (n = 3), 1 x 10(6) (n = 3), and 3 x 10(6) (n = 6) cells/kg in patients with AML in first complete remission (CR1) at high risk for recurrence. Before CNDO-109-NK cell administration, patients were treated with lymphodepleting fludarabine/cyclophosphamide. CNDO-109-NK cells were well tolerated, and no doselimiting toxicities were observed at the highest tested dose. The median relapse-free survival (RFS) by dose level was 105 (3 x 10(5)), 156 (1 x 10(6)), and 337 (3 x 10(6)) days. Two patients remained relapse-free in posttrial follow-up, with RFS durations exceeding 42.5 months. Donor NK cell microchimerism was detected on day 7 in 10 of 12 patients, with 3 patients having evidence of donor cells on day 14 or later. This trial establishes that CNDO-109-NK cells generated from related HLA haploidentical donors, cryopreserved, and then safely administered to AML patients with transient persistence without exogenous cytokine support. Three durable complete remissions of 32.6 to 47.6+ months were observed, suggesting additional clinical investigation of CNDO-109-NIK cells for patients with myeloid malignancies, alone or in combination with additional immunotherapy strategies, is warranted. (C) 2018 American Society for Blood and Marrow Transplantation.